Detailed explanation of the efficacy, role and side effects of dasatinib

Dasatinib (Dasatinib) is a member of the BCR-ABL tyrosine kinase inhibitor class of drugs and is commonly used for acute lymphoblastic leukemia, chronic myelogenous leukemia and leukemia.

The study showed that in patients with newly diagnosed chronic phase chronic myelogenous leukemia, the primary endpoint was confirmed complete cytogenetic response (CCyR) rate within 12 months, which was 76.8% in the dasatinib group and 66.2% in the imatinib group. 52.1% of patients reported a major molecular response to dasatinib and 33.8% to imatinib. In adults with imatinib-resistant or intolerant chronic phase chronic myelogenous leukemia with a minimum of 24 months of follow-up, dasatinib demonstrated efficacy of 92% hematological clinical response after 4 weeks, 63% cytogenetic response and 50% CCyR at 100 mg daily.

Dasatinib treatment was continued as long as there was no evidence of disease progression or unacceptable toxicity. Dasatinibwas well tolerated. After at least 24 months of follow-up, 77% of patients randomized to dasatinib and 75% of patients randomized to imatinib remained on study, and after at least 60 months of follow-up, 61% of patients taking dasatinib and 62% of patients taking imatinib remained on treatment.

In clinical trials, QTc prolongation was an adverse reaction in less than 1% of dasatinib treated patients, and 1% of patients had a QTcF greater than 500 milliseconds. Dasatinibuse has also been associated with myelosuppression, bleeding-related events, fluid retention, cardiovascular toxicity, pulmonary hypertension, severe dermatological reactions, tumor lysis syndrome, and hepatotoxicity. It may also cause embryo-fetotoxicity and cause adverse effects related to skeletal growth and development in pediatric patients.